Your browser doesn't support javascript.
loading
Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis.
Alnahhas, Iyad; Alsawas, Mouaz; Rayi, Appaji; Palmer, Joshua D; Raval, Raju; Ong, Shirley; Giglio, Pierre; Murad, Mohammad Hassan; Puduvalli, Vinay.
Afiliação
  • Alnahhas I; Division of Neuro-Oncology, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Alsawas M; Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.
  • Rayi A; Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Palmer JD; Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Raval R; Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Ong S; Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Giglio P; Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Murad MH; Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.
  • Puduvalli V; Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Neurooncol Adv ; 3(1): vdab095, 2021.
Article em En | MEDLINE | ID: mdl-34258581
ABSTRACT
[This corrects the article DOI 10.1093/noajnl/vdaa082.].
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article